CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Insulin glargine

Last Updated: September 4, 2015
Result type: Reports
Project Number: SE0451-000
Product Line: Reimbursement Review

Generic Name: Insulin glargine

Brand Name: Basaglar

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Diabetes mellitus, type 1; diabetes mellitus, type 2

Indications: Diabetes mellitus, Type 1 & 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 14, 2016

Recommendation Type: List with clinical criteria and/or conditions